ipd 1

Sex Pheromone Inhibitor iPD1 is a compound that functions as an inhibitor of the sex pheromone cPD1 [1].

Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.

Suplatast Tosilate (IPD 1151T) is a novel capsular anti-asthmatic drug with an IC50 above 100 μM, inhibiting both IgE production and the synthesis of IL-4 and IL-5.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1/PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).

Anti-PD-1 Antibody (8P789) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human PD-1.

Lomvastomig is a bispecific antibody that targets PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune response. It is designed for cancer treatment by promoting T cell activation and overcoming immune suppression. [Molecular weight: 145.34 kDa]

Rilvegostomig is a bispecific humanized IgG1 antibody targeting the immune-regulating receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T cell activation, fostering a robust anti-tumor immune response, especially in cancers such as non-small cell lung cancer (NSCLC). Molecular weight: 146.06 KD.